Pay in 4 interest-free payments of $7.16 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
In the Phase 2 trial, participants lost up to 24 percent of body weight over 48 weeks at the highest dose
APC resistance is a primary contributor to the risk of developing blood clots in carriers of the mutation
Roles of synuclein in gastrointestinal microbiome dysbiosisrelated Parkinsons disease progression (review)
Anxiety disorders create a predisposition to palpitation awareness and to the physiological conditions that produce them
Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label
It means regulators have assessed its manufacturing, efficacy, adverse-event data, contraindications and benefitrisk profile for defined groups of patients
US$ 20.88
US$ 24.84
US$ 27.99
US$ 23.19
US$ 28.06
US$ 27.29
